Clinical Trials Logo

Carcinoma, Transitional Cell clinical trials

View clinical trials related to Carcinoma, Transitional Cell.

Filter by:
  • Approved for marketing  
  • Page 1

NCT ID: NCT04136808 Approved for marketing - Clinical trials for Locally Advanced or Metastatic Urothelial Carcinoma (UC)

An Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma

Start date: n/a
Phase:
Study type: Expanded Access

The primary purpose of this expanded access program is to evaluate safety and tolerability of enfortumab vedotin (EV) in participants in the United States with locally advanced or metastatic urothelial carcinoma (UC) who have exhausted standard of care therapies and are not eligible to participate in an ongoing EV clinical study. This program will also evaluate the efficacy of EV.

NCT ID: NCT02589717 Approved for marketing - Clinical trials for Urothelial Carcinoma

An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy

Start date: November 2015
Phase: Phase 4
Study type: Expanded Access

This is an open-label, multicenter, single-arm, expanded access program (EAP) designed to provide atezolizumab access to participants with locally advanced or metastatic urothelial carcinoma that has progressed on, or is intolerant to, a platinum-containing chemotherapy regimen.